The Role of Immunotherapy in Multiple Myeloma

Pharmaceuticals

Mehmet Kocoglu¹  Ashraf Badros¹  Ashkan Emadi² 

[1] Marlene and Stewart Greenebaum Cancer Center, University of Maryland Medical Center, Baltimore, MD 21201, USA

关键词: myeloma;    immunotherapy;    vaccines;    tumor antigens;    antibodies;    CAR-T;    adoptive cell therapy;   

DOI  :  10.3390/ph9010003

来源: mdpi

【 摘 要 】

Multiple myeloma is the second most common hematologic malignancy. The treatment of this disease has changed considerably over the last two decades with the introduction to the clinical practice of novel agents such as proteasome inhibitors and immunomodulatory drugs. Basic research efforts towards better understanding of normal and missing immune surveillence in myeloma have led to development of new strategies and therapies that require the engagement of the immune system. Many of these treatments are under clinical development and have already started providing encouraging results. We, for the second time in the last two decades, are about to witness another shift of the paradigm in the management of this ailment. This review will summarize the major approaches in myeloma immunotherapies.

【 授权许可】

CC BY   
© 2016 by the authors; licensee MDPI, Basel, Switzerland.